<DOC>
	<DOC>NCT02063659</DOC>
	<brief_summary>The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.</brief_summary>
	<brief_title>Telotristat Etiprate for Carcinoid Syndrome Therapy</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<criteria>Patients ≥ 18 years of age All patients of reproductive potential must agree to use an adequate method of contraception during the study and for 12 weeks after the Followup visit. Histopathologicallyconfirmed, welldifferentiated metastatic neuroendocrine tumor Documented history of carcinoid syndrome Patient is able and willing to provide written informed consent prior to participation Presence of diarrhea attributed to any condition other than carcinoid syndrome. Presence of 12 or more watery bowel movements per day Positive stool examination for enteric pathogens, pathogenic ova or parasites, of Clostridium difficile at Screening Karnofsky Performance Status ≤ 60% Presence of any clinically significant laboratory, medical history, or physical examination findings deemed unacceptable by the Investigator A history of short bowel syndrome History of constipation within 2 years of Screening Life expectancy &lt; 12 months from Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>